A Unified Product Structure for Innovative Product Development and Manufacturing of Reference Biomaterials in a Regulated Environment: The MicroQuant™ Case Study

The transition of novel biomaterial technologies from research and development into manufacturing environments presents considerable organizational, technical, and regulatory challenges, especially when the final products must adhere to stringent standards imposed by regulated industries or compendial guidance. A core challenge in this transition is establishing a cohesive product structure that effectively bridges innovative product development with the precision, consistency, and compliance demands of manufacturing. Misalignment between these domains can result in inefficiencies, quality variations, extended timelines, and elevated organizational risk. 

Here, we present a case study describing the implementation of an innovative, unified product structure at ATCC for the development and manufacture of MicroQuant™, a portfolio of reference biomaterials designed to minimize microbial culture time for end users in QC laboratories. The MicroQuant™ portfolio comprises 37 authenticated and precisely quantitated products delivered in an easy-to-use format. These products were developed as reference materials using a novel preservation technology developed at ATCC and were manufactured under ISO 9001, ISO/IEC 17025, and ISO 17034 guidance. While the program faced challenges typical of translating innovative architectures into a manufacturing-ready system, MicroQuant™ exemplifies how a cohesive product structure can reliably support progression from initial concept through validated manufacturing within a regulated setting. 

The case study outlines the strategic approach used to integrate product development, process design, quality assurance, and regulatory compliance while preserving scientific integrity and functional performance. We describe a harmonized manufacturing framework that incorporates modular process design, real-time analytical control, and risk-based quality decision making to enable rapid iteration during early development and seamless scaleup to ISO 17034–aligned operations. By leveraging data-driven process characterization, in-process monitoring, and automated documentation pipelines, we reduced development cycle times for MicroQuant™ without compromising material homogeneity, stability, or traceability.

Key outcomes include: (1) establishing traceable value-assignment pathways compatible with ISO 17034 and ISO/IEC 17025 requirements, (2) implementing statistically robust approaches for batch comparability and reference value verification, and (3) reducing manufacturing variability through integrated control strategies. Our results show that adaptive manufacturing improves responsiveness to customers and regulatory expectations while delivering reproducible, high-quality biomaterials suitable for cross-platform analytical standardization.

This work illustrates a scalable model for producing next-generation biomaterials that meet reference material accreditation requirements. The MicroQuant™ case study highlights actionable strategies that can be adopted across the biomanufacturing ecosystem to accelerate innovation and strengthen confidence in biomaterial-based measurement systems.